S&P DJI Announces March 2024 Quarterly Rebalance
Filed with ASX · · 8 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- VivaGel BV US FDA Appeal Outcome
- Viraleze shows antiviral efficacy in COVID-19 patients
- VivaGel BV sales and distribution agreement MENA region
- Positive DEP docetaxel Phase 2 results
- AGM Chairman's address and CEO presentation
Later from Starpharma
- Starpharma and Medicxi Partnership Petalion Therapeutics
- Starpharma Business Update
- Positive final DEP irinotecan Phase 2 clinical trial results
- Annual Report to shareholders
- Starpharma Receives $5.5M R&D Tax Incentive Refund
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma